Scalability 2024

Advancing AAV production scalability: enhancing purity, productivity, and yield

Cell & Gene Therapy Insights 2024; 10(2), 181–186

DOI: 10.18609/cgti.2024.026

Published: 19 March
Ashish Saksule

Abi Pinchbeck, Commissioning Editor, Cell & Gene Therapy Insights, speaks to Ashish Saksule, Principal Scientist, Vector Core Lead, Vertex Pharmaceuticals, about ongoing efforts to improve vector productivity and titer, addressing issues with the separation of empty and full capsids, and increasing scalability in the downstream enrichment of AAV.